Failed in phase 2

Amiloride: protect nerve tissue in secondary progressive MS

secondary progressive MS · Axonal protection / ion channels / excitotoxicity

Controlled phase 2 trials did not meet their main goal for this group.

Trials
1
Running now
0
Controlled phase 2/3 trials
1
People in controlled trials
445

Human genetics

Genes linked to MS that these medicines act on: SCN3A

How the verdict was reached

Negative in phase 2

TrialPhaseParticipantsStartedResultCounted
MS-SMARTPhase 24452014Missed its main goal

No difference was noted between any active treatment and placebo in PBVC (amiloride vs placebo, 0·0% [95% CI -0·4 to 0·5; p=0·99]; fluoxetine vs placebo -0·1% [-0·5 to 0·3; p=0·86]; riluzole vs placebo -0·1% [-0·6 to 0·3; p=0·77]).

Paper abstract		Counted

Counted: 1. Will count later: 0. Not counted: 0.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • Oct 2026Status changed from Results pending to Failed in phase 2
  • Oct 2026Status changed from Failed in phase 2 to Results pending
  • Oct 2026First listed as Failed in phase 2

Related hypotheses

Assembled by software from public sources.